JP2011518125A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518125A5
JP2011518125A5 JP2011501904A JP2011501904A JP2011518125A5 JP 2011518125 A5 JP2011518125 A5 JP 2011518125A5 JP 2011501904 A JP2011501904 A JP 2011501904A JP 2011501904 A JP2011501904 A JP 2011501904A JP 2011518125 A5 JP2011518125 A5 JP 2011518125A5
Authority
JP
Japan
Prior art keywords
seq
fab fragment
heavy chain
light chain
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011501904A
Other languages
English (en)
Japanese (ja)
Other versions
JP5438095B2 (ja
JP2011518125A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/037349 external-priority patent/WO2009120530A1/en
Publication of JP2011518125A publication Critical patent/JP2011518125A/ja
Publication of JP2011518125A5 publication Critical patent/JP2011518125A5/ja
Application granted granted Critical
Publication of JP5438095B2 publication Critical patent/JP5438095B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011501904A 2008-03-27 2009-03-17 グルカゴン受容体アンタゴニスト Expired - Fee Related JP5438095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27
US61/039,907 2008-03-27
PCT/US2009/037349 WO2009120530A1 (en) 2008-03-27 2009-03-17 Glucagon receptor antagonists

Publications (3)

Publication Number Publication Date
JP2011518125A JP2011518125A (ja) 2011-06-23
JP2011518125A5 true JP2011518125A5 (enExample) 2012-04-12
JP5438095B2 JP5438095B2 (ja) 2014-03-12

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011501904A Expired - Fee Related JP5438095B2 (ja) 2008-03-27 2009-03-17 グルカゴン受容体アンタゴニスト

Country Status (15)

Country Link
US (2) US7968686B2 (enExample)
EP (1) EP2268670A1 (enExample)
JP (1) JP5438095B2 (enExample)
KR (1) KR101235934B1 (enExample)
CN (1) CN101983208A (enExample)
AR (1) AR070844A1 (enExample)
AU (1) AU2009228866A1 (enExample)
BR (1) BRPI0910118A2 (enExample)
CA (1) CA2719761A1 (enExample)
CL (1) CL2009000586A1 (enExample)
EA (1) EA201071126A1 (enExample)
MX (1) MX2010010517A (enExample)
PE (1) PE20091674A1 (enExample)
TW (1) TW201000126A (enExample)
WO (1) WO2009120530A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482350B (zh) * 2009-09-08 2015-08-05 株式会社新药 作用于胰高血糖素受体的抗体及其应用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
DK2663579T3 (en) 2011-01-14 2017-07-31 Univ California THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
WO2013081993A1 (en) 2011-12-02 2013-06-06 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
SG11201508264UA (en) * 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
BR112016028726A2 (pt) * 2014-06-08 2017-11-07 Remd Biotherapeutics Inc métodos de tratamento de um paciente diagnosticado com diabetes tipo 1, métodos de redução, supressão, atenuação ou inibição de um ou mais sintomas associados com t1d, e métodos de tratamento de um paciente que está em risco de t1d
KR102708864B1 (ko) 2016-08-30 2024-09-25 리제너론 파마슈티칼스 인코포레이티드 글루카곤 수용체 신호전달을 간섭함에 의한 중증 인슐린 저항성의 치료 방법
WO2018075792A1 (en) 2016-10-20 2018-04-26 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
UA129078C2 (uk) 2017-01-27 2025-01-08 Енджіем Байофармасьютикалз, Інк. Білки, що зв'язують глюкагонові рецептори, та способи їх застосування
US12139546B2 (en) 2017-08-22 2024-11-12 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁(杭州)生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
WO2020125744A1 (zh) 2018-12-21 2020-06-25 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
ATE285472T1 (de) 1992-08-28 2005-01-15 Novo Nordisk As Glucagonrezeptoren
US6909031B2 (en) 2000-12-06 2005-06-21 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CN101484081A (zh) 2006-07-04 2009-07-15 布拉科成像S.P.A.公司 生物组织尤其是肿瘤组织等的局部热切除装置
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Similar Documents

Publication Publication Date Title
JP2011518125A5 (enExample)
JP2020079252A5 (enExample)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
JP2020500538A5 (enExample)
JP2012504955A5 (enExample)
JP2022061992A5 (enExample)
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP2011517447A5 (enExample)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2019504032A5 (enExample)
JP2013538553A5 (enExample)
JP2018108081A5 (enExample)
JP2009225799A5 (enExample)
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2018521638A5 (enExample)
JP2011528902A5 (enExample)
JP2020517249A5 (enExample)
JP2012504634A5 (enExample)
JP2015522252A5 (enExample)
JP2010534478A5 (enExample)
JP2017514461A5 (enExample)
JP2010516229A5 (enExample)
JP2020508303A5 (enExample)
JP2012513214A5 (enExample)